Perspective Therapeutics (NYSE:CATX) lost ~22% in the premarket on Thursday after the cancer drug developer posted results ...

Originally founded in Switzerland in 1904 and then sold in the U.S. market as early as 1915, Ovaltine is a chocolate powder ...

The company made its debut last year with a $51 million Series A and a licensing agreement with Astellas for a gene therapy ...